ALP-modified glutathione targeted nano-liposome as well as preparation method and application thereof

Targeting nanoliposomes by ALP-modified glutathione, encapsulating GSH in liposomes and utilizing the targeting of alkaline phosphatase, solves the low bioavailability and insufficient precise delivery in osteoporosis. The problem of achieving efficient treatment of osteoporosis.

CN119015229AInactive Publication Date: 2024-11-26FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411316921.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing GSH has low bioavailability and insufficient precise delivery in the treatment of osteoporosis. Traditional delivery methods have the problem of decomposition of drugs in the gastrointestinal tract and the inability to achieve precise delivery of specific cells.

Method used

Glutathione modified with ALP is used to target nanoliposomes, and targeted delivery of osteoblasts is achieved by encapsulating GSH in specially made liposomes and leveraging the high specific binding ability of alkaline phosphatase.

Benefits of technology

It improves the bioavailability of GSH, reduces side effects, significantly improves the enrichment of drugs in bone tissue, promotes bone formation and inhibits bone resorption, and provides an efficient treatment plan for osteoporosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015229A_ABST
    Figure CN119015229A_ABST
Patent Text Reader

Abstract

The invention discloses an ALP-modified glutathione targeted nano-liposome as well as a preparation method and application thereof, and belongs to the technical field of drug delivery. The preparation method comprises the following steps: mixing phosphatidylcholine, cholesterol and polyethylene glycol modified distearoyl phosphatidyl ethanolamine, dissolving in a solvent, carrying out rotary evaporation to obtain a lipid membrane, and carrying out water bath and ultrasonic treatment to obtain a liposome suspension; mixing an alkaline phosphatase solution, the liposome suspension and a cross-linking agent, and stirring for reaction to obtain ALP modified liposome suspension; and mixing a glutathione solution with the ALP-modified liposome suspension, carrying out stirring reaction, and carrying out ultrasonic treatment to obtain the ALP-modified glutathione liposome. According to the invention, the alkaline phosphatase is used as a targeting ligand to modify the surface of the liposome, so that the enrichment degree of the drug in bone tissues is remarkably improved, systematic side effects are reduced, the damage of oxidative stress to osteoblasts is reduced, the growth and repair of the bone tissues are promoted, and the biocompatibility and safety are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug delivery, and in particular to an ALP-modified glutathione-targeted nanoliposome and a preparation method and application thereof. Background Art

[0002] Osteoporosis in the elderly is a common metabolic bone disease characterized by decreased bone mass and destruction of bone tissue microstructure, which significantly increases the risk of fractures. Although current treatments are helpful to a certain extent, they have problems such as low drug delivery efficiency and large side effects. Nanoliposomes as drug carriers show advantages such as good biocompatibility and biodegradability, but they still lack effective targeting in the treatment of osteoporosis.

[0003] Glutathione (GSH) is a tripeptide naturally present in biological cells, composed of glutamic acid, cysteine ​​and glycine. GSH is one of the most important antioxidants in cells and is essential for maintaining the reduced state of cells and resisting oxidative stress. In the treatment of osteoporosis, the antioxidant properties of GSH are particularly critical for protecting osteoblasts from damage by reactive oxygen species (ROS), helping to promote bone formation and inhibit bone resorption.

[0004] However, traditional delivery methods of GSH, including oral and intravenous injection, face the challenges of low bioavailability and insufficient precise delivery: when delivered orally, GSH is easily broken down by enzymes in the gastrointestinal tract, resulting in low bioavailability; although intravenous injection can directly enter the blood circulation, it cannot achieve precise delivery to specific cells, increasing the risk of side effects. Summary of the invention

[0005] In order to solve the above technical problems, the purpose of the present invention is to provide an ALP-modified glutathione targeted nanoliposome and a preparation method and application thereof, so as to solve the problems of low bioavailability and insufficient precise delivery of existing GSH in the treatment of osteoporosis.

[0006] The technical solution of the present invention to solve the above technical problems is as follows:

[0007] A method for preparing ALP-modified glutathione-targeted nanoliposomes comprises the following steps:

[0008] (1) firstly, phosphatidylcholine, cholesterol and polyethylene glycol-modified distearoylphosphatidylethanolamine are mixed and dissolved in a solvent, then rotary evaporated to obtain a lipid film, and finally ultrasonically treated in a water bath to obtain a liposome suspension;

[0009] (2) mixing an alkaline phosphatase solution, the liposome suspension obtained in step (1), and a cross-linking agent, and stirring the mixture to obtain an ALP-modified liposome suspension;

[0010] (3) mixing the glutathione solution with the ALP-modified liposome suspension obtained in step (2), stirring for reaction, and ultrasonically treating to obtain the product.

[0011] The beneficial effects of the present invention are as follows: the present invention adopts alkaline phosphatase (ALP) as a targeting substance, and provides a precise drug delivery strategy by encapsulating GSH into special liposomes. The selection of ALP is based on its high expression level on the surface of osteoblasts and its excellent biocompatibility, which provides an efficient drug delivery strategy for the treatment of osteoporosis. The high specific binding ability of ALP and its natural role in bone metabolism produce a synergistic effect with the drug delivery system, further improving the therapeutic effect. ALP-modified liposomes not only improve the bioavailability of GSH, but also reduce side effects, providing an innovative solution for the treatment of bone diseases such as osteoporosis.

[0012] Furthermore, in step (1), the molar ratio of phosphatidylcholine, cholesterol and polyethylene glycol-modified distearoylphosphatidylethanolamine is (30-60): (40-60): (1-1.5); the solvent is chloroform; and the concentration of polyethylene glycol-modified distearoylphosphatidylethanolamine in the mixed solution is 1-10 mg / mL.

[0013] Furthermore, in step (1), the temperature of the water bath is 55-65° C., the power of the ultrasonic treatment is 100-200 W, and the time is 5-10 min.

[0014] Furthermore, in step (1), the liposome suspension after ultrasonic treatment is purified by centrifugation and filtration.

[0015] The beneficial effect of adopting the above further technical solution is: the present invention ensures the accuracy and repeatability of the liposome preparation process through the above preparation process, and provides an efficient and stable platform for the drug delivery system.

[0016] Furthermore, in step (2), the concentration of the alkaline phosphatase solution is 1-3 mg / mL; the molar ratio of alkaline phosphatase to liposome is 1:(100-500); the cross-linking agents are EDC and NHS, and the molar ratio of alkaline phosphatase, EDC and NHS is (0.8-1.2):(0.8-1.2):(0.8-1.2).

[0017] Furthermore, in step (2), the pH of the stirring reaction is 7.2-7.4, the temperature is 20-30° C., and the time is 30-60 min.

[0018] Furthermore, after the stirring reaction in step (2), the obtained suspension is purified by dialysis, ultracentrifugation and filtration in sequence, and the ALP-modified liposome suspension is obtained after resuspending.

[0019] Furthermore, dialysis is performed using a 12000-14000 Dalton dialysis bag at 4°C, ultracentrifugation is performed at a centrifugal force of 100000-200000 g for 2-4 h, and filtration is performed using a 0.22 micron or 0.45 micron filter.

[0020] The beneficial effect of adopting the above further technical scheme is that the present invention effectively removes unreacted EDC, NHS and unbound ALP through purification methods such as dialysis, ultracentrifugation and filtration, thereby ensuring high purity and high stability of the prepared ALP modified liposomes.

[0021] Furthermore, in step (3), the concentration of the glutathione solution is 1-10 mg / mL, and the mass of glutathione is 5-20% of the mass of the ALP-modified liposomes.

[0022] Furthermore, in step (3), the stirring reaction time is 30-90 min, and the power of ultrasonic treatment is 100-200 W, and the time is 5-15 min.

[0023] The beneficial effects of adopting the above further technical solution are as follows: the present invention ensures the uniform dispersion and effective loading of GSH in liposomes through ultrasonic treatment, improves the loading efficiency, and ensures the stability of liposomes.

[0024] Furthermore, in step (3), the suspension obtained after ultrasonic treatment is centrifuged to remove aggregates or unloaded glutathione, and the final concentration is adjusted using PBS buffer.

[0025] The beneficial effects of adopting the above further technical solution are as follows: the present invention improves the loading efficiency of GSH through the process of centrifugal resuspension, thereby ensuring the stability and biocompatibility of liposomes.

[0026] An ALP-modified glutathione-targeted nanoliposome is prepared by adopting the preparation method.

[0027] Application of the ALP-modified glutathione-targeted nanoliposomes in the preparation of osteoporosis drugs.

[0028] A drug for treating osteoporosis, comprising the above-mentioned ALP-modified glutathione-targeted nanoliposome.

[0029] The present invention has the following beneficial effects:

[0030] The present invention provides an ALP-modified glutathione targeted nanoliposome and a preparation method thereof. By modifying alkaline phosphatase as a targeting ligand on the surface of the liposome, the specific binding of ALP to the surface receptor of osteoblasts in bone tissue is utilized to significantly increase the enrichment of the drug in the bone tissue. This targeting strategy not only enhances the local concentration of the drug, but also reduces the systemic side effects by reducing the distribution to non-target tissues. In addition, the encapsulation of glutathione utilizes its powerful antioxidant properties, effectively neutralizes the reactive oxygen species in the bone cells, reduces the damage of oxidative stress to osteoblasts, and promotes the growth and repair of bone tissue. The biocompatibility of the liposome and the low toxicity of ALP ensure that the entire drug delivery system maintains the safety of treatment while improving the efficacy. Therefore, the present invention not only provides an efficient method for treating osteoporosis, but also provides a new possibility for the treatment of bone diseases through the synergistic effect of ALP and GSH. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 The schematic diagram of the structure of the ALP-modified glutathione-targeted nanoliposome prepared in Example;

[0032] Figure 2 It is a graph of the in vitro cumulative drug release percentage of the ALP-modified glutathione-targeted nanoliposomes in the test example;

[0033] Figure 3 The results of Alizarin Red S staining and ALP staining of bone tissue cells after treatment with ALP-modified glutathione targeted nanoliposomes in the experimental example;

[0034] Figure 4 This is a diagram showing the osteogenic effect of ALP-modified glutathione targeted nanoliposomes in the osteoporosis mouse model. DETAILED DESCRIPTION

[0035] The principles and features of the present invention are described below in conjunction with the accompanying drawings. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. If specific conditions are not specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0036] Embodiment 1:

[0037] A method for preparing ALP-modified glutathione-targeted nanoliposomes comprises the following steps:

[0038] (1) First, phosphatidylcholine (PC), cholesterol (Chol) and polyethylene glycol-modified distearoylphosphatidylethanolamine (PEG-DSPE) were mixed and dissolved in chloroform to form a uniform solution, wherein the molar ratio of PC, cholesterol Chol and PEG-DSPE was 45:50:1.5, wherein the concentration of PEG-DSPE in the solution was 1.8 mg / mL; then, the solvent was removed by rotary evaporation at 40°C and a rotation speed of 120 rpm to form a uniform lipid film; then, the lipid film was heated in a 60°C water bath and subjected to ultrasonic treatment at a power of 150 W for 8 min to achieve hydration of the lipid film and obtain a liposome suspension; finally, the solution was centrifuged at a centrifugal force of 100,000 g for 10 min and sterilized by filtration through a 0.22 μm filter to complete purification and obtain pure liposomes.

[0039] (2) ALP was first dissolved in phosphate buffer, mixed with the liposomes obtained in step (1), and EDC and NHS were added as cross-linking agents. The concentration of the ALP solution was 2 mg / mL, and the molar ratio of ALP, EDC, NHS and the liposomes obtained in step (1) was 1:1:1:300. Then, the pH was adjusted to 7.2-7.4 at room temperature and stirred for 45 minutes to complete the covalent connection. Finally, the covalently connected ALP-modified liposomes were dialyzed 5 times at 4°C using a 13,000 Dalton dialysis bag and the PBS buffer was replaced to remove unreacted EDC, NHS and unbound ALP. The liposome layer was separated by centrifugation at a centrifugal force of 150,000 g for 3 hours, filtered and sterilized through a 0.22 μm filter, and resuspended to obtain a 100 mg / mL ALP-modified liposome suspension.

[0040] (3) GSH was first dissolved in phosphate buffer to obtain a GSH solution with a concentration of 10 mg / mL, and then mixed with the ALP-modified liposome suspension obtained in step (2) at a volume ratio of 1:1. After mixing, the mixture was stirred at room temperature for 1 hour, and then ultrasonicated for 10 minutes at a power of 150 W using a probe ultrasonicator. Interval ultrasonication was used to avoid overheating of the solution. After the ultrasonication was completed, the aggregates or unloaded GSH were removed by centrifugation, and the final concentration was collected and adjusted using PBS buffer to obtain an ALP-modified glutathione targeted nanoliposome suspension with a concentration of 55 mg / mL. The structural schematic diagram of the obtained ALP-modified glutathione targeted nanoliposome is shown in FIG. Figure 1 shown.

[0041] Embodiment 2:

[0042] A method for preparing ALP-modified glutathione-targeted nanoliposomes comprises the following steps:

[0043] (1) First, phosphatidylcholine (PC), cholesterol (Chol) and polyethylene glycol-modified distearoylphosphatidylethanolamine (PEG-DSPE) were mixed and dissolved in chloroform to form a uniform solution, wherein the molar ratio of PC, Chol and PEG-DSPE was 30:40:1, and the concentration of PEG-DSPE in the solution was 1.2 mg / mL; then, the solvent was removed by rotary evaporation at 40°C and a rotation speed of 120 rpm to form a uniform lipid film; then, the lipid film was heated in a 60°C water bath and subjected to ultrasonic treatment at a power of 150 W for 8 min to achieve hydration of the lipid film and obtain a liposome suspension; finally, the suspension was centrifuged at a centrifugal force of 100,000 g for 10 min and filtered through a 0.22 μm filter for sterilization to complete purification and obtain pure liposomes.

[0044] (2) ALP was first dissolved in phosphate buffer, mixed with the liposomes obtained in step (1), and EDC and NHS were added as cross-linking agents. The concentration of the ALP solution was 2 mg / mL, and the molar ratio of ALP, EDC, NHS and the liposomes obtained in step (1) was 1:1:1:500. Then, the pH was adjusted to 7.2-7.4 at room temperature and stirred for 45 minutes to complete the covalent connection. Finally, the covalently connected ALP-modified liposomes were dialyzed 5 times at 4°C using a 13,000 Dalton dialysis bag and the PBS buffer was replaced to remove unreacted EDC, NHS and unbound ALP. The liposome layer was separated by centrifugation at a centrifugal force of 150,000 g for 3 hours, filtered and sterilized through a 0.22 μm filter, and resuspended to obtain a 200 mg / mL ALP-modified liposome suspension.

[0045] (3) Firstly, GSH was dissolved in phosphate buffer to obtain a GSH solution with a concentration of 10 mg / mL, and then mixed with the ALP-modified liposome suspension obtained in step (2) at a volume ratio of 1:1. After mixing, the mixture was stirred at room temperature for 1 hour, and then ultrasonicated for 10 minutes at a power of 150 W using a probe ultrasonicator. Interval ultrasonication was used to avoid overheating of the solution. After the ultrasonication was completed, the aggregates or unloaded GSH were removed by centrifugation, and the final concentration was collected and adjusted using PBS buffer to obtain an ALP-modified glutathione targeted nanoliposome suspension with a concentration of 105 mg / mL.

[0046] Embodiment 3:

[0047] A method for preparing ALP-modified glutathione-targeted nanoliposomes comprises the following steps:

[0048] (1) First, phosphatidylcholine (PC), cholesterol (Chol) and polyethylene glycol-modified distearoylphosphatidylethanolamine (PEG-DSPE) were mixed and dissolved in chloroform to form a uniform solution, wherein the molar ratio of PC, Chol and PEG-DSPE was 60:60:1, and the concentration of PEG-DSPE in the solution was 1.2 mg / mL; then, the solvent was removed by rotary evaporation at 40°C and a rotation speed of 120 rpm to form a uniform lipid film; then, the lipid film was heated in a 60°C water bath and subjected to ultrasonic treatment at a power of 150 W for 8 min to achieve hydration of the lipid film and obtain a liposome suspension; finally, the suspension was centrifuged at a centrifugal force of 100,000 g for 10 min and sterilized by filtration through a 0.22 μm filter to complete purification and obtain pure liposomes.

[0049] (2) ALP was first dissolved in phosphate buffer, mixed with the liposomes obtained in step (1), and EDC and NHS were added as cross-linking agents. The concentration of the ALP solution was 2 mg / mL, and the molar ratio of ALP, EDC, NHS and the liposomes obtained in step (1) was 1:1:1:100. Then, the pH was adjusted to 7.2-7.4 at room temperature and stirred for 45 minutes to complete the covalent connection. Finally, the covalently connected ALP-modified liposomes were dialyzed 5 times at 4°C using a 13,000 Dalton dialysis bag and the PBS buffer was replaced to remove unreacted EDC, NHS and unbound ALP. The liposome layer was separated by centrifugation at a centrifugal force of 150,000 g for 3 hours, filtered and sterilized through a 0.22 μm filter, and resuspended to obtain a 66.7 mg / mL ALP-modified liposome suspension.

[0050] (3) GSH was first dissolved in phosphate buffer to obtain a GSH solution with a concentration of 10 mg / mL, and then mixed with the ALP-modified liposome suspension obtained in step (2) at a volume ratio of 1:1. After mixing, the mixture was stirred at room temperature for 1 hour, and then sonicated for 10 minutes at a power of 150 W using a probe sonicator. Interval sonication was used to avoid overheating of the solution. After sonication, the aggregates or unloaded GSH were removed by centrifugation, and the final concentration was collected and adjusted using PBS buffer to obtain an ALP-modified glutathione targeted nanoliposome suspension with a concentration of 38.35 mg / mL.

[0051] Embodiment 4:

[0052] A method for preparing ALP-modified glutathione-targeted nanoliposomes comprises the following steps:

[0053] (1) First, phosphatidylcholine (PC), cholesterol (Chol) and polyethylene glycol-modified distearoylphosphatidylethanolamine (PEG-DSPE) were mixed and dissolved in chloroform to form a uniform solution, wherein the molar ratio of PC, Chol and PEG-DSPE was 45:50:1.5, and the concentration of PEG-DSPE in the solution was 1.8 mg / mL; then, the solvent was removed by rotary evaporation at 40°C and a rotation speed of 120 rpm to form a uniform lipid film; then, the lipid film was heated in a 60°C water bath and subjected to ultrasonic treatment at a power of 150 W for 8 min to achieve hydration of the lipid film and obtain a liposome suspension; finally, the solution was centrifuged at a centrifugal force of 100,000 g for 10 min and filtered through a 0.22 μm filter for sterilization to complete purification and obtain pure liposomes.

[0054] (2) ALP was first dissolved in phosphate buffer, mixed with the liposomes obtained in step (1), and EDC and NHS were added as cross-linking agents. The concentration of the ALP solution was 2 mg / mL, and the molar ratio of ALP, EDC, NHS and the liposomes obtained in step (1) was 1:1:1:300. Then, the pH was adjusted to 7.2-7.4 at room temperature and stirred for 45 minutes to complete the covalent connection. Finally, the covalently connected ALP-modified liposomes were dialyzed 5 times at 4°C using a 13,000 Dalton dialysis bag and the PBS buffer was replaced to remove unreacted EDC, NHS and unbound ALP. The liposome layer was separated by centrifugation at a centrifugal force of 150,000 g for 3 hours, filtered and sterilized through a 0.22 μm filter, and resuspended to obtain a 50 mg / mL ALP-modified liposome suspension.

[0055] (3) GSH was first dissolved in phosphate buffer to obtain a GSH solution with a concentration of 10 mg / mL, and then mixed with the ALP-modified liposome suspension obtained in step (2) at a volume ratio of 1:1. After mixing, the mixture was stirred at room temperature for 1 hour, and then sonicated for 10 minutes at a power of 150 W using a probe sonicator. Interval sonication was used to avoid overheating of the solution. After sonication, the aggregates or unloaded GSH were removed by centrifugation, and the final concentration was adjusted using PBS buffer to obtain an ALP-modified glutathione targeted nanoliposome suspension with a concentration of 30 mg / mL.

[0056] Comparative Example 1:

[0057] A method for preparing ALP-modified glutathione-targeted nanoliposomes comprises the following steps:

[0058] (1) First, phosphatidylcholine (PC), cholesterol (Chol) and polyethylene glycol-modified distearoylphosphatidylethanolamine (PEG-DSPE) were mixed and dissolved in chloroform to form a uniform solution, wherein the molar ratio of PC, Chol and PEG-DSPE was 45:50:1.5, and the concentration of PEG-DSPE in the solution was 1.8 mg / mL; then, the solvent was removed by rotary evaporation at 40°C and a rotation speed of 120 rpm to form a uniform lipid film; then, the lipid film was heated in a 60°C water bath and subjected to ultrasonic treatment at a power of 150 W for 8 min to achieve hydration of the lipid film and obtain a liposome suspension; finally, the liposome was purified by centrifugation at a centrifugal force of 100,000 g for 10 min and filtered through a 0.22 μm filter for sterilization to obtain pure liposomes, which were resuspended in PBS buffer to obtain a liposome suspension with a concentration of 55 mg / mL.

[0059] (2) Firstly, GSH was dissolved in phosphate buffer to obtain a GSH solution with a concentration of 10 mg / mL, and then mixed with the liposome suspension obtained in step (1) at a volume ratio of 1:1. After mixing, the mixture was stirred at room temperature for 1 hour, and then ultrasonicated for 10 minutes at a power of 150 W using a probe ultrasonicator. Interval ultrasonication was used to avoid overheating of the solution. After the ultrasonication was completed, the aggregates or unloaded GSH were removed by centrifugation, and the final concentration was adjusted using PBS buffer to obtain a glutathione-targeted nanoliposome suspension with a concentration of 100 mg / mL.

[0060] Test example:

[0061] (1) Constructing an osteoporosis cell model, the method is as follows: Select osteoblast (MC3T3-E1) cell line, culture cells in Dulbecco's Modified Eagle's Medium (DMEM) culture medium containing 10% fetal bovine serum (FBS) until the confluence reaches 70-80%. The osteoporosis inducer dexamethasone is added to simulate the microenvironment of osteoporosis. The drug treatment is divided into experimental group 1, experimental group 2 and control group. The ALP-modified glutathione-targeted nanoliposome suspension obtained in Example 2 is added to experimental group 1, with a concentration of 1 μg / mL; the ALP-modified glutathione-targeted nanoliposome suspension obtained in Example 3 is added to experimental group 2, with a concentration of 1 μg / mL; the glutathione-targeted nanoliposome suspension obtained in comparative example 1 is added to the control group, with a concentration of 1 μg / mL. The final addition amount should be adjusted according to the concentration of the liposome suspension and the volume of the culture medium. If the concentration of the liposome suspension is 100 mg / mL, then for 1 mL of culture medium, 10 μL of liposome suspension needs to be added to reach a concentration of 1 μg / mL. Cultivate for 40 hours to observe the cell absorption effect and cell activity, and calculate the cumulative percentage of drug release. The cumulative percentage of drug release is usually calculated by measuring the amount of drug released from the liposomes into the culture medium. Collect samples at predetermined time points (such as 0, 1, 2, 3, 4, 8, 10, 24, 40 hours), separate the liposomes and the drugs released into the solution by centrifugation, and for each time point, multiply the measured drug concentration by the volume of the solution to obtain the total amount of drug released at that time point. The calculation formula is:

[0062]

[0063] The experimental results are as follows Figure 2 As shown, compared with Comparative Example 1, the ALP-modified glutathione-targeted nanoliposomes prepared in Example 2 and Example 3 achieved a higher cumulative sustained-release drug percentage in a short time, and can significantly improve the absorption rate of drugs by cells.

[0064] (2) Constructing an osteoporosis mouse model, the method is as follows: Select healthy adult female mice as experimental animals, and induce an osteoporosis model by ovarian removal surgery (Ovariectomy, OVX). And divide them into an experimental group and a control group, the experimental group is injected with ALP-modified glutathione targeted nanoliposomes prepared in Example 1 through the tail vein, the drug dose is 5 mg / kg, the control group 1 is injected with an equal amount of physiological saline through the tail vein, and the control group 2 is injected with an equal amount of liposomes prepared in Comparative Example 1 through the tail vein. Alizarin Red S staining and ALP staining are performed on bone tissue cells to detect the distribution of drugs in bone tissue and the therapeutic effect.

[0065] The experimental results are as follows Figure 3 and Figure 4 As shown, the experimental results show that compared with the control group 1 without liposome injection and the control group 2 injected with liposomes prepared by comparative document 1, the ALP-modified glutathione targeted nanoliposomes prepared by the present invention have higher drug loading efficiency, show better bone tissue targeting in vivo, can effectively increase bone density and improve osteoporosis symptoms, and show good therapeutic potential for the treatment of osteoporosis.

[0066] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing ALP-modified glutathione-targeted nanoliposomes, characterized in that: The following steps are involved: (1) firstly, phosphatidylcholine, cholesterol and polyethylene glycol-modified distearoylphosphatidylethanolamine are mixed and dissolved in a solvent, then rotary evaporated to obtain a lipid film, and finally ultrasonically treated in a water bath to obtain a liposome suspension; (2) mixing an alkaline phosphatase solution, the liposome suspension obtained in step (1), and a cross-linking agent, and stirring the mixture to obtain an ALP-modified liposome suspension; (3) mixing the glutathione solution with the ALP-modified liposome suspension obtained in step (2), stirring for reaction, and ultrasonically treating to obtain the product.

2. The method for preparing the ALP-modified glutathione-targeted nanoliposome according to claim 1, characterized in that: In the step (1), the molar ratio of phosphatidylcholine, cholesterol and polyethylene glycol-modified distearoylphosphatidylethanolamine is (30-60): (40-60): (1-1.5); the solvent is chloroform; and the concentration of polyethylene glycol-modified distearoylphosphatidylethanolamine in the mixed solution is 1-10 mg / mL.

3. The method for preparing the ALP-modified glutathione-targeted nanoliposome according to claim 1, characterized in that: In the step (1), the temperature of the water bath is 55-65° C., the power of the ultrasonic treatment is 100-200 W, and the time is 5-10 min.

4. The method for preparing the ALP-modified glutathione-targeted nanoliposome according to claim 1, characterized in that: The concentration of the alkaline phosphatase solution in step (2) is 1-3 mg / mL; the molar ratio of alkaline phosphatase to liposome is 1:(100-500); the cross-linking agents are 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide, and the molar ratio of alkaline phosphatase, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide is (0.8-1.2):(0.8-1.2):(0.8-1.2).

5. The method for preparing ALP-modified glutathione-targeted nanoliposomes according to claim 1, characterized in that: The pH of the stirring reaction in step (2) is 7.2-7.4, the temperature is 20-30° C., and the time is 30-60 min.

6. The method for preparing ALP-modified glutathione-targeted nanoliposomes according to claim 1, characterized in that: The concentration of the glutathione solution in step (3) is 1-10 mg / mL, and the mass of glutathione is 5-20% of the mass of the ALP-modified liposome.

7. The method for preparing ALP-modified glutathione-targeted nanoliposomes according to claim 1, characterized in that: The stirring reaction time in step (3) is 30-90 min, and the power of ultrasonic treatment is 100-200 W, and the time is 5-15 min.

8. An ALP-modified glutathione-targeted nanoliposome, characterized in that: The method is prepared by the preparation method according to any one of claims 1 to 7.

9. Use of the ALP-modified glutathione-targeted nanoliposomes according to claim 8 in the preparation of osteoporosis drugs.

10. A drug for treating osteoporosis, characterized in that: The invention comprises the ALP-modified glutathione-targeted nanoliposome as claimed in claim 8.

Citation Information

Patent Citations

  • Preparation method of glutathione lipidosome

    CN110507809A

  • Method for preparing double-layer modified reduced glutathione nano-liposome

    CN112006288A

  • Glutathione calcium chelate and its preparing method, use and composition

    CN1944457A